TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prolongation of lidocaine sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the lidocaine concentration‐versus‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall and understanding of study purpose and methods
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post-activation potentiation (PAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tetanic maximal torque potentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure of levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: death or moderate-to-severe CP
Endpoint domain: Mortality/survival
Primary endpoint: Rate of catheter occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: student preference for delivery platform
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact of pain on activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sputum smear-negative conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum culture-negative conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tunnel features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reaction forces in the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reaction moments in the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in repetition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Finger dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD Core subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Episodic Memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in QUICKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic reactogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in CIVIQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IMA/albumin ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in water swallow test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Candida spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in Staphylococcus spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decrease in mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean change in CGI-S score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of response (>or=50% improvement in HAM-D score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in diarrhea grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduced frequency of diarrhea grades 3 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient work of breathing (WOB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilator peak inspiratory flow (V(I))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative nausea (PON)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative vomiting (POV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of choroidal neovascularization (CNV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of geographic atrophy (GA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total volume of perioperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: end-diastolic index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acceleration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average SBP levels within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICH (Intracerebral Hemorrhage)
Endpoint domain: Adverse events/effects
Primary endpoint: decision-making index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head and neck QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of binocular vision without diplopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sizes of extraocular muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean final light threshold value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time taken to see the first light stimulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity to light stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low density lipoprotein cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in optical coherence tomography strut coverage at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTd values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS pain score during local anesthetic injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain score during sampling of the prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School attendance rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recovery of left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance at 6-minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in the Chalder fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Use of vasopressive drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant satisfaction with the DASH behavioural intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Nocturnal plasma glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal plasma insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Homeostasis model assessment of insulin resistance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean journey time difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial survival rates at 6 years
Endpoint domain: Mortality/survival
Primary endpoint: Laboratory response to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood in aspirated fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fluid aspirate yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality from sulfonylurea-induced severe hypoglycemia
Endpoint domain: Mortality/survival
Primary endpoint: Quality of treatment for diabetic emergencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance to the exam
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hypoxemia after endoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Facial pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complications (corneal involvement and masticatory weakness)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in physical or emotional symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in emotional function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lessening of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in manifest refraction values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative tricuspid regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete healing of donor sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Erythrocyte TGN concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response rate to fluoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positivity for ≥2 AAbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of CVD events
Endpoint domain: Mortality/survival
Primary endpoint: Detectable coronary artery calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scores in A and B areas of GMFM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation of supragingival calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of neonates
Endpoint domain: Mortality/survival
Primary endpoint: Cerebrospinal fluid lipid peroxides and antioxidant enzymes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological outcome at one month follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bronchoprotection improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient costs per visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Repigmentation of white patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute left hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eradication of MRSA
Endpoint domain: Adverse events/effects
Primary endpoint: LV peak +dP/dt response to dobutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MARCA-assessed MVPA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activPAL overall sitting decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activPAL light stepping increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean UCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectoscopy score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume normal activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recall of unpleasant induction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depressive symptoms reduction (PHQ-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptoms reduction (BDI-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate Aronchick grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen saturation (SpO2) maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of esomeprazole treatment test in confirming GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median induction-to-delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive accuracy of metrics for health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients meeting PRT criteria (30% reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of days per patient meeting PRT criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat Percentage (BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median CAP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without significant hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of oral treprostinil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week-8 culture negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of responders (CGI-I score <= 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRX3 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FTO expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of aspirin nonresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TXB2 levels >3.1 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Scale for Depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urinary free cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Preference for orally disintegrating tablets vs capsules
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients free of pyrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cell count on used lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of institutionalization
Endpoint domain: Mortality/survival
Primary endpoint: Probability of staying in community care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of masticatory muscle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar nitric oxide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ACT scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Excellent and good rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-made 9-score scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure to engage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dropout
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaccine completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabeculation through the defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased radiolucent rim around the graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early stage lung cancer detection rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of F dominant contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean values of attachment gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased GCF MMP‐8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased TIMP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of unnecessary biopsies
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of serum endotoxin, IL‐6, IL‐8, TNF and soluble IL‐2R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cVEMP and oVEMP response patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of prediabetes or diabetes at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-IR at 4 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient-reported discomfort during measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: severity of AP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Wexner score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximal tolerated volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain disability-free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Screening rates for any test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average motor and sensory onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean motor and sensory offset times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midazolam clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of distribution of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived workload appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infection rates per patient-year
Endpoint domain: Adverse events/effects
Primary endpoint: reduced risk of radiation to bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delayed time to moderate-to-severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevented worsening of pain and pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of back/low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of days on sick-leave due to back/low back pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sucrose solution most preferred (% wt/vol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight of aspirated airway mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔCL values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calculus removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interest in genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dental plaque retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume density of the villous capillaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes